Drug Trial News

RSS

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012

AstraZeneca plans to conduct ticagrelor plus clopidogrel clinical trial for PAD

AstraZeneca today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.

17 Jul 2012

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS).

17 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

Merck, known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer's Association International Conference (AAIC) being held in Vancouver, British Columbia, Canada on July 14-19, 2012.

16 Jul 2012

James J. Peters Veterans Hospital actively enrolls participants for NIC5-15 phase IIb trial in AD

The James J. Peters Veterans Hospital in Bronx, New York, is actively recruiting participants for a phase IIb clinical trial testing NIC5-15, a disease modifying candidate for Alzheimer's disease.

14 Jul 2012

ACT treats fourth patient in U.S. clinical trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).

13 Jul 2012

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today announced that patient dosing has begun in a Phase I clinical trial of OMP-54F28 in patients with advanced solid tumor cancers.

13 Jul 2012

Cubist initiates CB-315 Phase 3 trial for Clostridium difficile-associated diarrhea

Cubist Pharmaceuticals, Inc. today announced the initiation of its pivotal Phase 3 studies evaluating the efficacy and safety of CB-315 in patients with Clostridium difficile-associated diarrhea, or CDAD, with enrollment of a patient in the first of two planned identical global trials.

13 Jul 2012

Nottingham researchers to lead Avastin clinical study for AMD

Nottingham researchers are leading a study to test the effectiveness of a controversial drug in the treatment of a common loss of vision.

12 Jul 2012

Maraviroc reduces incidence of GvHD in blood cancer patients after bone marrow transplantation

An HIV drug that redirects immune cell traffic significantly reduces the incidence of a dangerous complication that often follows bone marrow transplants for blood cancer patients, according to research from the Perelman School of Medicine at the University of Pennsylvania that will be published today in the New England Journal of Medicine.

12 Jul 2012

New drug combination could offer hope to children with neuroblastoma

A new drug combination could offer hope to children with neuroblastoma - one of the deadliest forms of childhood cancer - by boosting the effectiveness of a promising new gene-targeted treatment.

12 Jul 2012

Merck announces update on odanacatib Phase III trial for osteoporosis

Merck, known as MSD outside the United States and Canada, announced today an update on the Phase III trial assessing fracture risk reduction with odanacatib, Merck's investigational cathepsin K (cat-K) inhibitor.

12 Jul 2012

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.

12 Jul 2012

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Spinal Restoration, Inc. announced today the completion of enrollment in the Phase III Investigational New Drug (IND) study of the Biostat System. The Phase III clinical trial is a 260-subject, randomized, blinded, placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain.

12 Jul 2012

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1.

12 Jul 2012

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

BioInvent International AB today announced data from the GLACIER phase IIa study evaluating BI-204 in patients with stable atherosclerotic vascular disease. BioInvent is developing BI-204 in collaboration with Genentech, a member of the Roche Group.

11 Jul 2012

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).

11 Jul 2012

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate.

11 Jul 2012

Drug Trial News

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

AstraZeneca plans to conduct ticagrelor plus clopidogrel clinical trial for PAD

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

James J. Peters Veterans Hospital actively enrolls participants for NIC5-15 phase IIb trial in AD

ACT treats fourth patient in U.S. clinical trial for Stargardt's Macular Dystrophy

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

Cubist initiates CB-315 Phase 3 trial for Clostridium difficile-associated diarrhea

Nottingham researchers to lead Avastin clinical study for AMD

Maraviroc reduces incidence of GvHD in blood cancer patients after bone marrow transplantation

New drug combination could offer hope to children with neuroblastoma

Merck announces update on odanacatib Phase III trial for osteoporosis

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Arrowhead initiates Adipotide Phase 1 trial in obesity

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News